Vijayshree Yadav

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi New disease-modifying therapies and new challenges for MS
    Vijayshree Yadav
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L226, Portland, OR 97239, USA
    Curr Neurol Neurosci Rep 12:489-91. 2012
  2. ncbi Complementary and alternative medicine for the treatment of multiple sclerosis
    Vijayshree Yadav
    Department of Neurology L226, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Expert Rev Clin Immunol 6:381-95. 2010
  3. ncbi Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters
    Vijayshree Yadav
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Mult Scler 16:387-97. 2010
  4. ncbi Complementary and alternative medicine: is there a role in multiple sclerosis?
    Vijayshree Yadav
    Department of Neurology L226, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Curr Neurol Neurosci Rep 6:259-67. 2006
  5. ncbi Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS
    Sonemany Salinthone
    Portland Veterans Affairs Medical Center, VAMC RD 8, 3710 Portland, OR 97239, USA
    Endocr Metab Immune Disord Drug Targets 8:132-42. 2008
  6. ncbi Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis
    Arthur A Vandenbark
    Neuroimmunology Laboratory, Department of Veterans Affairs Medical Center, Portland, OR 97239, USA
    Immunology 123:66-78. 2008
  7. ncbi A randomized pilot study of naturopathic medicine in multiple sclerosis
    Lynne Shinto
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    J Altern Complement Med 14:489-96. 2008
  8. ncbi Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study
    Vijayshree Yadav
    Department of Neurology, Oregon Health and Science University, L226, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Autoimmune Dis 2012:954739. 2012
  9. ncbi Apical ballooning resulting from limbic encephalitis
    Jill Gelow
    Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Am J Med 122:583-6. 2009
  10. ncbi The effects of omega-3 Fatty acids on matrix metalloproteinase-9 production and cell migration in human immune cells: implications for multiple sclerosis
    Lynne Shinto
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, CR 120, Portland, OR 97239, USA
    Autoimmune Dis 2011:134592. 2011

Research Grants

  1. Lipoic acid as an immune modulator in multiple sclerosis
    Vijayshree Yadav; Fiscal Year: 2007

Detail Information

Publications10

  1. ncbi New disease-modifying therapies and new challenges for MS
    Vijayshree Yadav
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L226, Portland, OR 97239, USA
    Curr Neurol Neurosci Rep 12:489-91. 2012
    ..It may also increase the risk of serious herpes infections and paradoxical activation of MS. More information is needed about these serious side effects from fingolimod to allow us to use it safely in patients...
  2. ncbi Complementary and alternative medicine for the treatment of multiple sclerosis
    Vijayshree Yadav
    Department of Neurology L226, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Expert Rev Clin Immunol 6:381-95. 2010
    ..There is very limited research evaluating the safety and effectiveness of CAM in MS. However, in recent years, the NIH and the National MS Society have been actively supporting the research in this very important area...
  3. ncbi Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters
    Vijayshree Yadav
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Mult Scler 16:387-97. 2010
    ..A dose of 1200 mg oral lipoic acid can achieve therapeutic serum levels in patients with multiple sclerosis...
  4. ncbi Complementary and alternative medicine: is there a role in multiple sclerosis?
    Vijayshree Yadav
    Department of Neurology L226, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Curr Neurol Neurosci Rep 6:259-67. 2006
    ..The research on CAM therapies in MS is still exploratory, but considering peoples' interest and common use of these therapies, further research in this area is clearly warranted...
  5. ncbi Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS
    Sonemany Salinthone
    Portland Veterans Affairs Medical Center, VAMC RD 8, 3710 Portland, OR 97239, USA
    Endocr Metab Immune Disord Drug Targets 8:132-42. 2008
    ....
  6. ncbi Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis
    Arthur A Vandenbark
    Neuroimmunology Laboratory, Department of Veterans Affairs Medical Center, Portland, OR 97239, USA
    Immunology 123:66-78. 2008
    ....
  7. ncbi A randomized pilot study of naturopathic medicine in multiple sclerosis
    Lynne Shinto
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    J Altern Complement Med 14:489-96. 2008
    ..Naturopathic medicine encompasses a broad range of CAM modalities and may improve quality of life in patients with MS...
  8. ncbi Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study
    Vijayshree Yadav
    Department of Neurology, Oregon Health and Science University, L226, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Autoimmune Dis 2012:954739. 2012
    ..The maximum tolerated dose of RTL1000 in MS subjects is 60 mg, comparable to effective RTL doses in EAE. RTL1000 is a novel approach for MS treatment that may induce immunoregulation without immunosuppression and promote neural repair...
  9. ncbi Apical ballooning resulting from limbic encephalitis
    Jill Gelow
    Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Am J Med 122:583-6. 2009
    ..Neurogenic stunned myocardium is an increasingly recognized cause of left ventricular apical ballooning, or takotsubo cardiomyopathy. We report the first case of neurogenic stunned myocardium as a result of limbic encephalitis...
  10. ncbi The effects of omega-3 Fatty acids on matrix metalloproteinase-9 production and cell migration in human immune cells: implications for multiple sclerosis
    Lynne Shinto
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, CR 120, Portland, OR 97239, USA
    Autoimmune Dis 2011:134592. 2011
    ..The data suggest that omega-3 fatty acids may benefit patients with multiple sclerosis by modulating immune cell production of MMP-9...

Research Grants1

  1. Lipoic acid as an immune modulator in multiple sclerosis
    Vijayshree Yadav; Fiscal Year: 2007
    b>Vijayshree Yadav, MD seeks funding for a Mentored Patient Oriented Research Career Development Award to obtain the skills necessary to design and conduct scientifically rigorous clinical trials...